neboglamine neboglamine neboglamine (inn) (developmental code names cr-2249, xy-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the nmda receptor which is under investigation for rottapharm for the treatment of schizophrenia and cocaine dependence. it shows cognition- and memory-enhancing effects in animal models. as of june 2015, it is in phase ii clinical trials for both schizophrenia and cocaine abuse. neboglamineclinical dataother namesnebostinel; n-(4,4-dimethylcyclohexyl)-l-α-glutamineatc codenoneidentifiers iupac name (4s)-4-amino-5--5-oxopentanoic acid cas number163000-63-3pubchem cid3074827chemspider2333649unii12ea34u5b8comptox dashboard (epa)dtxsid2045787 echa infocard100.162.081 chemical and physical dataformulac13h24n2o3molar mass256.346 g·mol−13d model (jsmol)interactive image smiles cc1(ccc(cc1)nc(=o)c(ccc(=o)o)n)c inchi inchi=1s/c13h24n2o3/c1-13(2)7-5-9(6-8-13)15-12(18)10(14)3-4-11(16)17/h9-10h,3-8,14h2,1-2h3,(h,15,18)(h,16,17)/t10-/m0/s1key:vcrglzypnnavrp-jtqlqieisa-n